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Abstract
Meniere’s disease or syndrome is one of the most common inner ear diseases.
Meniere’s disease is characterized by episodic vertigo, sensorineural hearing loss
that fluctuates during episodes, tinnitus, and ear fullness. Ideal treatment should
stop vertigo attacks, restore hearing, get rid of tinnitus and ear fullness. Treatment
options are decided upon the remaining hearing, severity, and intensity of vertigo
attacks. Meniere’s disease is progressive on hearing levels of the patient; some of
them develop profound hearing loss that also could affect the other ear. In order to
plan a treatment scheme for patient, these conditions should be assessed. It has a
destructive and progressive nature, so the first step of treatment should contain
more conservative treatment options. If symptom control could not be obtained,
destructive treatment options should be considered.
Keywords:Meniere’s disease, lifestyle changes, Meniett, vestibular rehabilitation,
neuro-otology
1. Introduction
Meniere’s disease was first described by Prosper Meniere in 1861 [1]. He
described series of symptoms of a leukemic patient, and he suggested that vertigi-
nous symptoms were caused by hemorrhage in the inner ear [2]. Knapp hypothe-
sized inner ear hydrops, but its histologic confirmation was demonstrated in 1938
[3]. Still today, Meniere’s disease etiology is not clear.
Meniere’s disease is characterized by episodic vertigo, sensorineural hearing loss
that fluctuates during episodes, tinnitus, and ear fullness. Some of the patients
develop drop attacks called Tumarkin crisis, also known as otolithic crisis, and
nausea [4, 5].
Meniere’s disease or syndrome is one of the most common inner ear diseases. Its
prevalence reported 3.5–513 per 100,000 in USA series [6]. It shows slightly female
predominance 1.89:1 [7]. It is more common in white and older population; peak
age is in the fourth and fifth decade but some early onset cases in children are
reported [8, 9].
Meniere’s usually starts in one ear, but bilateral disease is not uncommon. It may
occur many years after the unilateral symptoms first started. Its prevalence is
unclear and reported from 2 to 78% [9]. Familial Meniere’s disease has been
reported in 10–20% of cases [10]. Meniere’s disease is strongly associated with
Meniere’s disease so as allergies.
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Till this day, an effective treatment protocol is not established, because the
pathogenesis of Meniere’s disease is not clear.
2. Pathogenesis
Most common histopathologic finding is “endolymphatic hydrops” but the exact
pathology is unknown. The Committee on Hearing and Equilibrium of American
Academy of Otolaryngology Head and Neck Surgery’s (AAO-HNS) definition of
certain Meniere’s disease contains histopathologial confirmation of endolymphatic
hydrops [11].
Endolymph is produced by stria vascularis in the cochlea and by the dark cells in
the vestibular labyrinth [12]. In autopsy studies, endolymphatic hydrops was
observed in the temporal bones of patients who were diagnosed Meniere’s disease,
but not all individuals who had endolymphatic hydrops developed Meniere’s disease
symptoms [13, 14]. Perisaccular fibrosis and decreased endolymphatic duct size are
observed in some of the patients. The CT images showed that individuals have
hypoplastic endolymphatic sac and duct and inadequate periaqueductal
pneumatization [15]. MRI studies showed that patients with Meniere’s disease have
significantly smaller and shorter drainage system [16]. After gadolinium enhance-
ment, enhancement of endolymphatic sac and periventricular space was demon-
strated in MRI [17, 18]. Nakashima et al. designed a study to demonstrate
endolymphatic hydrops in Meniere’s disease in 3 Tesla MRI. Gadolinium was
injected transtympanically and MR images were taken a day after. They observed
that the gadolinium moves first into the perilymphatic space and that can reveal the
border between endolymph and perilymph. They successfully showed the endo-
lymphatic hydrops in these patients [19]. Naganawa et al. study demonstrated same
results with 1.5 Tesla MRI after intravenous administration of gadolinium. They
reported their waiting time is much shorter (4 hours after contrast enhancement)
and 95% success rate, while the intratympanic gadolinium method’s rate of success
is reported as 80–90% [20]. Imaging is also important as it helps in differential
diagnosis of the other cases that could cause unilateral hearing loss, vertigo such as
vestibular schwannoma.
It is hypothesized that the ruptures of membranous labyrinth and cicatrization
in healing process could cause the drain blockage that leads to endolymphatic
hydrops [21, 22]. Schuknect explained that, the ruptures of membranous labyrinth
cause the leakage of potassium enriched endolymph to perilymph depolarize the
nerve cells. Acute inactivation results with hearing loss and vertigo, after healing
process of the chemical distribution of ions normalize; so the effects are reversible.
Since the Meniere’s disease takes its course through lifetime, the effects on the inner
ear is irreversible at some point, so the hearing loss is permanent and vertigo attacks
subdue [23]. However, this theory is not accepted by all; some authors suggested
that ruptures are occurred rarely and not adequate to explain all the symptoms [24].
3. Etiology
Meniere’s syndrome is the triad; fluctuating hearing loss, tinnitus, and episodes
of vertigo; if the cause is unknown it is defined as Meniere’s disease [25]. In exper-
imental studies, the blockage of endolymphatic duct and its lead to endolymphatic
hydrops is shown in animals. In order to create this, mechanical blockage, viral
inoculation, and immune response-induced inflammation are used [26].
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Some of the studies suggested that allergy and Meniere’s disease could be linked.
Derebery et al. studied patients who were diagnosed with Meniere’s disease. The
skin prick test results were positive of 41% of these patients, which were three times
higher than general population [27]. Some mechanisms were proposed in order to
explain the link between allergy and Meniere’s disease.
1.The fenestrated blood vessels that are located in endolymphatic sac allow the
antigen to enter that leads to mast cell degranulation. Inflammation around the
perisaccular fibrous tissue and release of histamine cause vasodilatation and
increase the secretion that causes endolymphatic sac resorption capacity over
rules.
2. Immune complexes that enter the endolymphatic sac circulation through this
fenestrated vessels start inflammation and increase vascular permeability.
3.Waldeyer’s ring stimulated by viral antigens triggers T-cell migration to
endolymphatic sac and leads to inflammation and excession of fluid
production [28].
In order to demonstrate this relationship, Derebery et al. investigated the effects
of allergen immunotherapy and elimination of food allergens in Meniere’s disease
patients. Their results were surprisingly positive. They reported that the improve-
ment of symptoms of Meniere’s disease and allergic symptoms were significant [29].
Another mechanism that is suggested is viral infection; however, no specific
virus is identified [30].
Ischemia is another factor that is suggested in Meniere’s disease mechanism [31].
Migraine and Meniere’s disease link by vascular mechanism [32].
4. Diagnosis
In order to plan a treatment algorithm for Meniere’s disease, it is important to
diagnose it accurately. Diagnostic investigation is not bound to only one test result.
The Committee on Hearing and Equilibrium of the AAO-HNS has described the
symptoms. As per AAO-HNS, the major symptoms of Meniere’s disease are vertigo,
hearing loss, and tinnitus [11].
4.1 Vertigo
Spontaneous, rotational vertigo that last at least 20 minutes accompanied usually
with nausea and vomiting which are the definitive spells of Meniere’s disease.
During the spell, horizontal or horizontal rotatory nystagmus is observed.
4.2 Hearing loss
Fluctuating hearing loss, commonly in low frequencies, is the most common
audiological finding. In some cases, hearing loss is progressive and is usually
unilateral.
Hearing loss is described as:
• the arithmetic mean of hearing thresholds of 250, 500, and 1000 Hz which is
15 dB or higher than the average of 1000, 2000, and 3000 Hz; or,
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• average threshold of 500, 1000, 2000, and 3000 Hz which is 20 dB or higher in
poorer ear in unilateral cases; or
• average threshold of 500, 1000, 2000, and 3000 Hz which is higher than 25 dB
in bilateral cases.
About 10 dB change or more or 15% or more change in speech discrimination
rate is considered clinically significant.
One of the prognostic factors that affects hearing function is duration of the
disease [33]. It is documented by most of the authors [34–36]. Age is also an
independent prognostic factor to determine hearing function and its responsiveness
to medical treatment [37].
4.3 Tinnitus and aural fullness
It could be confirmed with the patients’ history. Tinnitus is commonly of a
low-frequency type [38]. Sometimes, patients describe it to be localized in affected
ear or sense it in the whole head. Patients describe tinnitus differently from each
other [39].
4.4 Clinical presentation
The initial symptom of Meniere’s disease can be vertigo (37%), tinnitus (18%),
fluctuating hearing loss (20%), or any combination of these. Only 25% of cases start
with all of these symptoms [40].
Most of the patients describe recurrent vertigo attacks (96.2%) with tinnitus
(91.1%) and ipsilateral hearing loss (87.7%) [41]. Most of the crippling symptom is
vertigo. In an acute attack, it tends to stay 20 minutes to 24 hours [42].
The beginning of the Meniere’s disease differs from patient to patient as well as
the course of the disease. It is found that vertigo stops in 57% of the patients in
2 years and 71% of the cases in 8.3 years after the first onset [43].
Detailed clinical history should be taken as the first and most important step for
diagnosis. Most of the distressing symptom is vertigo. It is usually present in hori-
zontal axis, accompanied with nausea and vomiting. During this attack, horizontal
or horizontal rotatory nystagmus could be observed.
Some of the patients could describe sudden drop attacks which were described
by Tumarkin, and this symptom is named after him also called otolithic crisis of
Tumarkin. This symptom is caused by utriculosaccular dysfunction [44]. Sudden
changes in vertical gravity reference cause postural adjustments via vestibulospinal
pathway and end up with sudden fall [45]. About 2–6% of patients with Meniere’s
disease were reported to experience drop attack [46].
Second common symptom is hearing loss usually accompanied with tinnitus and
ear fullness sensation. Hearing loss is fluctuating, most in low frequencies and tends
to be progressive; however, only 1–2% of patients end up with profound hearing
loss [47]. Additionally, 43.6% of the patients have different perception of hearing
between ears (diplacusis) and 56% recruitment [25].
Tinnitus description could be different between patients but it is usually
nonpulsatile and could be continuous or appears only during the attack, or could get
worse during the attacks.
The AAO-HNS Committee on Hearing and Equilibrium suggested staged diag-
nosis for Meniere’s disease. They suggested to group patients in the order of their
symptoms as possible, probable, definite, and certain Meniere’s disease [11]
(Table 1).
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The AAO-HNS Committee on Hearing and Equilibrium revised their diagnostic
criteria in 2015. The new definition of “Definite” and “Probable”Meniere’s disease
is summed up in Table 2 [48].
4.4.1 Diagnostic workup
To treat Meniere’s disease successfully, diagnosis should be confirmed. There is
not a single test exists to confirm Meniere’s disease alone, so the patient should be
evaluated with possible diagnostic tests.
4.4.2 Videonystagmography
Eye movements are observed after caloric or vestibular stimulation. Caloric
response is found to decrease in 48–73.5% of the patients’ affected ear, and com-
plete absence is reported in 6–11% of patients [49, 50].
4.4.3 Electrocochleography
Summation potentials are larger and more negative in Meniere’s disease. Most
valuable ratio is summation potential/action potential. SP/AP ratio is found to be
increased in Meniere’s disease. However, this is not definitive, and only 62% of
patients with Meniere’s disease have elevated ratios [51].
Possible Meniere’s
disease
• Episodic vertigo without documented hearing loss, or
• Sensorineural hearing loss (fluctuating or flat) with disequilibrium but
without definitive vertigo attacks
Probable Meniere’s
disease
• One definite vertigo episode
• Documented hearing loss at least once
• Tinnitus or ear fullness
Definite Meniere’s
disease
• Two or more definite vertigo attacks lasted at least 20 minutes
• Documented hearing loss at least one
• Tinnitus or ear fullness
Certain Meniere’s
disease
• Definite Meniere’s disease
• Histopathological confirmation of endolymphatic hydrops
Table 1.
Diagnosis of Meniere’s disease.
Probable Meniere’s
disease
• Two or more spontaneous episodes of vertigo (each lasts 20 minutes to
24 hours)
• Fluctuating aural symptoms on the affected ear (tinnitus, hearing loss, or
aural fullness)
• Other vestibular diseases were excluded
Definite Meniere’s
disease
• Two or more spontaneous episodes of vertigo (each lasts 20 minutes to
12 hours)
• Low- to mid-frequency sensorineural hearing loss in affected ear
(documented with audiometry) at least on one occasion (before, during, or
after the vertigo episode)
• Fluctuating aural symptoms on the affected ear (tinnitus, hearing loss, or
aural fullness)
• Other vestibular diseases were excluded
Table 2.
Amended 2015 criteria for diagnosis of Meniere’s disease.
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4.4.4 Dehydrating agents
Dehydrating agent such as glycerol, urea used to reduce endolymph volume and
improvement of symptoms were such as improved hearing, reduction of SP nega-
tivity in electrocochleography, trying to be observed. It is reported 60% sensitivity
for Meniere’s disease [52].
4.4.5 Vestibular evoked myopotentials
Loud clicks are used to stimulate stapedial movement in order to stimulate the
saccule. Stimulation saccule triggers the pathway that relaxes sternocleidomastoid
muscle. Normal ear response is recorded as 500 Hz, and affected ear’s response is
recorded in elevated thresholds with flattened tuning [53].
The AAO-HNS’s guideline is suggested in 1995 and does not contain these diag-
nostic vestibular battery; it is only suggested to the use of full audiometric workup.
One of the recent guidelines for diagnosis and treatment of Meniere’s disease is
from French Otorhinolaryngology-Head and Neck Surgery Society (SFORL) in
2016. They describe that “definite”Meniere’s disease could be diagnosed if another
cause could not be described to explain the following four clinical findings;
• two or more rotational vertigo attacks that last 2 minutes to 12 hours or,
Tumarkin’s crises;
• low-frequency hearing loss on two consecutive frequencies, 30 dB or more if
the other ear hearing is normal, or 35 dB or more if hearing is affected
bilaterally; and
• tinnitus or aural fullness; and
• fluctuating otologic findings.
MRI of inner ear is suggested to rule out cerebellopontine angle or endolym-
phatic sac tumors, anatomic deformity, or a degenerative pathology such as multi-
ple sclerosis that could mimic the symptoms of Meniere’s disease. Also
audiovestibular workup could lead the clinician to intralabyrintine pressure disor-
der. The workup should include at least pure-tone and speech audiometry with
VNG or VEMP or VHIT [54].
5. Treatment
Ideal treatment should stop vertigo attacks, restore hearing, and get rid of
tinnitus and ear fullness. Unfortunately, ideal treatment is absent nowadays. Our
limited knowledge of pathophysiology of the disease makes it impossible to treat
patients ideally. Also symptoms and course of the disease differ between patients,
so treatment should be individualized.
The aim of the treatment is to reduce frequency and severity of vertigo attacks
and improve hearing results [55]. All current treatment options are symptomatic.
Due to natural course of the disease, vertigo attacks of 60–80% of patients
improve without any intervention [56, 57]. Patients who refused to take any medi-
cal or surgical assistance had spontaneous improvement of their symptoms at the
rate of 71% [43]. Green et al. reported complete vertigo control in 50% of the
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patients, partial control in 28% of the patients, and only 17% of their patient needed
medical treatment in their 14 years of follow-up [58].
Treatment options are decided upon the remaining hearing, severity, and inten-
sity of vertigo attacks. Meniere’s disease is progressive on hearing levels of the
patient; some of them develop profound hearing loss which also could affect the
other ear. In order to plan a treatment scheme for a patient, these conditions should
be assessed. It has destructive and progressive nature, so the first step of treatment
should contain more conservative treatment options. If symptom control could not
be obtained, destructive treatment options should be considered.
AAO-HNS suggested a staging system based on a four-tone average of 500,
1000, 2000, and 3000 Hz on the worst pure-tone audiometry, and this system
should be obtained to the patients who were diagnosed with “definite” or “certain”
Meniere’s disease (Table 3) [11].
International Consensus (ICON) on treatment of the Meniere’s disease proposed
a treatment algorithm in 2018 (Figure 1) [59].
ICON’s proposal for treatment algorithm summarizes the logic of the treatment
for Meniere’s disease. When the course of the disease is considered, Meniere’s
disease could make the affected ear to deteriorate and also could affect the other ear
Stage Four-tone average (dB)
I 25 or less
II 26–40
III 41–70
IV >70
Table 3.
Staging of definite and certain Meniere’s disease.
Figure 1.
Treatment algorithm of Meniere’s disease proposed by ICON in 2018.
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at any time. Most logical approach for treatment is starting with less invasive option
and assessing the patient periodically. If the suggested treatment fails, more inva-
sive methods should be offered.
Also in SFORL guideline of treatment, a step-by-step approach from conserva-
tive to destructive is suggested.
If a patient seeks for medical attention during vertigo attack, treatment is
symptomatic. The rest of the chapter contains nonsurgical treatment options, acute
attack treatment, and vestibular rehabilitation options.
5.1 Preventive treatment options
5.1.1 Lifestyle changes and low salt diet
The first line of treatment is to encourage the patient to change his lifestyle into
a healthier one. Regulation of sleeping cycle, avoiding stress, caffeine, alcohol, and
tobacco, and changing into a low salt diet should be advised [60–62]. Caffeine is
accused to increase the endolymph volume due to its sympathomimetic actions, and
it is suggested to be restricted to 100 mg/day by AAO-HNS [63]. More active
lifestyle should be offered, like taking at least 20 minutes of walking.
Low salt diet has been suggested to Meniere’s disease patients since the 1930s,
where daily intake of sodium is recommended to be under 2 grams [64, 65]. Low
salt intake increases serum aldosterone levels [66]. It has been found that endolym-
phatic sac contains receptors for mineral corticoids [67]. Aldosterone controls Na/K
ATPase, thiazide-sensitive Na/Cl co-transporter, and epithelial Na channels which
are also expressed on endolymphatic sac [68–73]. It has been shown that
canrenoate, an aldosterone antagonist, reduced electrical potentials of endolym-
phatic sac after applied [74, 75]. Elevation of aldosterone levels may increase the
endolymph absorption [70]. However, restriction of salt intake could not be proven
to change the levels of sodium of plasma and endolymph [64, 65, 76].
In Miyashita et al.’s study, Meniere’s disease patients were grouped in order to
their sodium intake. After initiation of low sodium diet, patients were observed for
2 years. Low sodium group (daily intake of 3 grams or less) had better hearing levels
and less vertigo attacks than high sodium group (daily intake more than 3 grams).
However, serum aldosterone levels were not different although low sodium group
had higher serum levels [77].
Also Tadros and colleagues investigated elder population and those who had
higher serum aldosterone levels had better hearing levels, and they suggested that
aldosterone might have a protective effect on hearing [78].
Low sodium intake has known benefits on cardiovascular health; hence, there is
no harm to suggest it.
5.1.2 Betahistine
Betahistine is a weak histamine H1 receptor agonist and a potent histamine H3
receptor antagonist.
It is suggested to improve microvascular circulation in stria vascularis that
reduces the endolymph pressure [79], and it inhibits vestibular nuclei activity that
results longer and easier recovery [80, 81]. It reaches its peak plasma concentration
in 1 hour, and maximal therapeutic effects start in 3–4 hours after intake [82].
Betahistine is a popular agent in Europe and Japan. FDA does not approve its use
in vertigo as it is not commonly used in the USA. Its beneficial effects are based on
the clinical observation; some studies report favorable results on vertigo control and
hearing improvement and some studies do not. In betahistine’s case, literature
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findings are controversial. In SFORL guideline, betahistine is suggested as the first
line of treatment.
Tootoonchi et al. reported improvement of 6.35 dB in hearing levels after
6 months of betahistine administration [37]. However, patient’s first hearing levels
should be considered; if the patient has poor hearing levels at the first visit, he is less
likely to benefit from the treatment [36]. Cochrane reviews support the positive
effect of betahistine on vertigo attack frequency and hearing levels. They
highlighted the fact that the investigated studies have serious study design flaws
and tend to bias [83]. Therapeutic benefits of betahistine were reported in Nauta’s
meta-analysis [84].
BEMED study is a multi-central, placebo-controlled study that investigates the
effects of betahistine. The results on vestibular symptoms were not any different
compared to placebo [85]. In order to establish the benefits of betahistine, more
well-designed, placebo-controlled studies are required.
Literature seems to be controversial but it is suggested as the first line of treat-
ment in the European, French, and Japanese guidelines as its beneficial effects on
patients are observed clinically.
5.1.3 Diuretics
Another treatment agent widely used for Meniere’s disease treatment is
diuretics. Thiazide group of diuretics is usually suggested. The cells that produce
endolymph, such as dark cells and stria vascularis, contain carbonic anhydrase.
Carbonic anhydrase inhibitors like acetazolamide are recommended in order to
reduce the production endolymph [86].
Recent systematic review on diuretics was conducted by Crowson and col-
leagues. They reviewed four retrospective studies. One of the studies compared
betahistine and diuretics and reported improved results on vertigo in both groups
but lack of placebo group [87]. In another study, diuretics showed beneficial effects
on vestibular symptoms compared to placebo [88]. Another placebo-controlled
retrospective study reported beneficial effects of hydrochlorothiazide on hearing
loss and vertigo control [89]. Most of the studies have low level of evidence.
Cochrane report in 2006 on diuretics reported beneficial but it highlighted the fact
that most of the studies were lack of high quality of evidence [90]. However, studies
indicate improvement in vertigo and lesser effect on hearing. Still they are
suggested as the first line of treatment options in many guidelines.
5.1.4 Pulse pressure treatment
Around three decades ago, it has been reported that positive pressure to middle
ear could have helped release of Meniere’s disease’s symptoms [91]. The underlying
mechanism is still unclear. Meniett device was introduced by Medtronic company
in 2000 and approved by FDA for Meniere’s disease treatment. After insertion of a
ventilation tube, the device is placed to external ear canal and sends low-pressure
pulses.
There are many studies about Meniett’s effect on Meniere’s disease and symptom
control. Gates et al.’s randomized controlled studies showed benefits of Meniett
device in short term. They demonstrated a significant decrease of vertigo attacks in
first 3 months but this could not be observed in long term [92]. Other studies
reached different conclusions about Meniett.
Ahsan et al. suggested that Meniett could be useful for Meniere’s disease treat-
ment, but Syed and van Sonsbeek were unable to show this effect in their random-
ized controlled studies where they compared the device effect to placebo [93–95].
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Recent meta-analysis reported that Meniett device provided complete remission of
52% of patients and 34% of patients had not complete but significant release of
symptoms [96]. This meta-analysis also investigated the suggested treatment pro-
tocols. Initiation of Meniett after 2 weeks of ventilation tube insertion seemed to
have better control over the symptoms. Effects on vertigo seem to begin in first
6 months, reach its peak in 6–18 months, and stabilize after 18 months. Also it was
observed that the shorter initiation of the therapy after placement of ventilation
tube had a better effect on hearing preservation and vertigo control [96].
However, some authors have different opinions when it comes to ventilation
tubes. They suggest that ventilation tube insertion alone could control Meniere’s
disease symptoms [97–100]. In hypoxia theory, it is hypothesized that vertigo
attacks are triggered by anoxia in inner ear, which can decrease endolymphatic
potentials and microcirculation of cochlea [101, 102]. Ventilation tube enriches
middle ear oxygenation and helps anoxic environment of inner ear [103]. Also
ventilation tube decreases the middle ear pressure, and it is hypothesized that this
could help to balance the increased inner ear pressure that could lead to Meniere’s
attack [104]. It remains inconclusive that the decrease of symptoms after Meniett
device is only from the ventilation tube or ventilation tube insertion alone. How-
ever, Zhang et al.’s meta-analysis reviewed studies that compare Meniett to placebo
device and reached a conclusion. They report that if the interval between ventila-
tion tube insertion and Meniett device is longer than 2 weeks, beneficial effects may
be due to Meniett device alone [96].
Recent Cochrane database reviewed Meniett device-based studies that were
published until 2014. Randomized controlled trials that compare Meniett and pla-
cebo devices were included in their study. Due to heterogeneity of data, calculation
of outcome was reported not possible. Most of the studies found no significant
difference between Meniett and placebo on vertigo control. Only one study showed
a significant vertigo control after 8 weeks of usage of Meniett. Secondary outcomes
like improvement on hearing, Meniett group significantly had better outcomes with
7.38 dB increase, effects on tinnitus and aural fullness could not be determined due
to heterogeneity of data. Their conclusion is that data due to these studies are not
adequate to determine the beneficial effects of Meniett [95].
Long-term results of Meniett device was published by Dornhoffer et al. Treated
patients’ improvement rates reported 75%, similar of untreated patients [105].
University of Colorado stated that the device is expensive and lacks cost-
beneficiality [106].
None of the studies that investigated Meniett device reported any complications.
Therefore it is harmless to propose this treatment. It is advised as the first-line
treatment of ICON’s guideline as well as Italian and Australian treatment algorithms
[59, 95]. It is reported as the most common second-line treatment option in the USA
[107]. With its potential benefits and low risk of complication rates, Meniett device
could be advised to patients.
5.1.5 Ventilation tubes
Though it is a surgical procedure, it is minimally invasive so its effects onMeniere’s
disease will be discussed in this chapter. After myringotomy of the anteroinferior
quadrant of tympanic membrane, ventilation tube could be inserted as an office
procedure. Sugawara et al. and Montandon et al. reported that ventilation tube inser-
tion has control over Meniere’s disease symptoms without further treatment [97, 98].
Kimura and Hutta’s experimental study on guinea pigs is that the middle ear
ventilation reduced endolymphatic hydrops. It is hypothesized that ventilation of
middle ear decreases the pressure in middle and inner ear [103].
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Tumarkin was the first physician who introduced ventilation tubes as a treat-
ment option in 1966. Tumarkin also reported that eustachian tube dysfunction is
correlated with endolymphatic hydrops and his data was supported by Lall
[108, 109]. However, Cinnamond, Hall, and Brackmann reported that eustachian
tube dysfunction was not always observed with Meniere’s disease patients and
insertion of ventilation tube could worsen the symptoms of patients [110, 111].
Montadon et al. reported that complete remission or improvement rates of their
patients were 82%. They also reported that the patient whose ventilation tube
blocked had recurrence of symptoms and immediate relief after reinsertion of
ventilation tubes [98]. Thomsen published results of patients who received
transmastoid endolymphatic decompression surgery compared with patients who
were inserted ventilation tube. Each group had significant control over their symp-
toms but found no difference between these groups [112].
Among the most recent studies in literature in 2015, Ogawa et al. studied venti-
lation tube insertion and its effects on intractable Meniere’s disease patients. All of
their patients were treated medically at least 6 months before ventilation tube
insertion was advised. After a year, 20% of their patients had complete remission,
47% had partial remission. Two years later, complete vertigo control rates increased
to 47%. Secondary benefits of procedure on hearing levels had no significant dif-
ference. They reported that ventilation tube insertion could be beneficial and post-
poned more invasive procedures [100]. Therefore, it could be advised as a first-line
surgical procedure to patients who have symptoms after medical treatment.
The SFORL guideline does not recommend this procedure due to lack of evi-
dence [54]. Not considered in ICON’s guideline or the European Position Statement
on diagnosis and Treatment of Meniere’s disease [59, 113].
However, it is worthwhile to try because literature findings of some authors
showed beneficial effects and it is minimally invasive and has low-complication
rates.
5.1.6 Intratympanic steroid injections
Intratympanic steroid treatment will be discussed in later chapters.
5.2 Treatment of acute attacks
It is important to control the effects and related vegetative symptoms of vertigo
during acute attack. Meniere’s attacks are sudden onset and could last 20 minutes to
24 hours. In order to suppress the symptoms, benzodiazepines, meclizine, or other
antihistamines could be used [106]. Drugs that are used to suppress the symptoms
of Meniere’s disease have no effect on progression of the disease.
Antihistamines, such as dimenhidrate, meclizine, benzodiazepines, and scopol-
amine, and anti-dopamines, which had antiemetic effects, such as metoclopramide
and fenotiazines, are used to suppress the vestibular symptoms. These agents also
have sedative effects that could help to reduce the patients’ anxiety. Diazepam is
effective on GABA receptors in vestibular nucleus and inhibits their response. It
should only be used during acute attack because the long-term usage decreases
vestibular compensation mechanisms. Dimenhidrate could also provide
relief during acute attack but it could affect concentration and cause dizziness in
long term [114].
Diazepam inhibits vestibular response with its effect on GABA-ergic receptors
located in cerebellar system [115]. However, clinical and experimental studies show
that the long-term usage of diazepam prolongs the vestibular compensation
[116, 117].
11
Meniere’s Disease: Nonsurgical Treatment
DOI: http://dx.doi.org/10.5772/intechopen.85573
Meclizine is useful to reduce vegetative symptoms like nausea, benzodiazepines
are also well tolerated anxiolytic, in order of intractable vomiting promethazine
suppositories could be used [106].
Transdermal scopolamine patches reaches therapeutic blood level 4 hours after
placement and release drug to system 72 hours; however, this could not be useful
because of the attacks’ sudden onset nature [118].
Intravenous lidocaine has found to be effective during acute attack of Meniere’s
disease [119].
5.3 Vestibular rehabilitation and psychological support
Meniere’s disease is a chronic attack characterized by their sudden onset. It is
observed by most of the physicians that it also burdens patients psychologically.
Also it is observed that stress and anxiety could trigger the attacks. Increase of
vertigo severity is associated with worse quality of life scores of Meniere’s disease
[120]. Most of the guidelines suggest psychological support and behavioral therapy
for the patients so they could have a better understanding of their condition and
help themselves to cooperate with this condition.
Van Cruijsen et al. suggested that the symptoms could be worsened in negative
emotional state [121]. Many studies reported the relation between symptoms and
behavioral characteristics; the worse perception of the disease could create a vicious
circle [122–124]. Patients suffering from Meniere’s disease were found to be having
more stress-causative behavioral characteristics than normal controls. This infor-
mation leads to hypothesis that higher stress-related hormone levels could cause
endolymphatic hydrops [124]. Another study by Van Cruijsen that assesses the
psychological state of Meniere’s disease patients compared to patients who had
chronic vestibular diseases documented that 63% of Meniere’s disease patients had
psychologic pathology, such as depression or anxiety, but found no significant
difference between non-Meniere’s disease patients. It is also reported that
Meniere’s disease patients quality of life questionnaire results were worse than
normal results [125].
Yokota et al. studied the treatment outcomes of both surgical and nonsurgical
treatment due to patients’ psychological status. Patients who had no mental distress
had benefitted from both of the treatments more than the patients who had mental
problems. Also surgical treatment options tend to have been found more beneficial
over nonsurgical treatment among the patients who had psychological disorders. In
order to improve treatment results of both surgical and nonsurgical options, it is
advised that psychological support is necessary [126].
Better understanding of the disease and psychological state and their relation
with better results seem to be beneficial for patients. Healthier psychology, encour-
agement to participate in active life, and providing psychological support in any
chronic illness are important to help patients to remain as functional individuals in
the society.
Traditionally, vestibular rehabilitation is ineffective in episodic vertigo patients.
Stable conditions are better candidates for successful rehabilitation. Due to its
chronic and progressive nature, rehabilitation of these patients is tricky. In order to
obtain rehabilitation, physical therapy must be customized. It is not advised to
initiate a rehabilitation program in acute onset.
The success of rehabilitation depends on the patient. First step of a successful
rehabilitation program is education of the patient. Each patient is unique, and their
characteristics, mental status, and understanding capacity differ between each
other. Patients have to be informed about their disease, its nature and treatment
options. Detailed explanation should be given about the effectiveness of physical
12
Meniere’s Disease
therapy, coping mechanisms, and possible sequels for each person’s understanding
level. It is also important to correct the patient if they were misinformed [127].
Before customizing a rehabilitation program, the patient should be examined
systemically. Mecagni et al.’s study demonstrated that limited ankle motion range
affects the patient’s performance on balance tests [127]. Lower extremities should be
examined on their functional levels and sense of proprioception. Impaired vision
could affect oculomotor functions negatively. In order to determine relationships
between the input mechanisms of balance system, posturography could be used if it is
available [128]. It is reported that static platform posturography is more sensitive and
specific in Meniere’s disease than caloric and rotational tests, both in diagnosing and
detecting other deficits that accompany these patients’ vestibular system [129, 130].
Although there is not a test battery that could predict the effects of attacks on
patients daily life, most of the patients describe the attacks debilitating [131]. Most
of the time attacks occur suddenly and being prepared for those attacks is impor-
tant. It should be discussed with the patient about special sensations or feelings
before the attack. At least half of the patients could identify a trigger [132]. In order
to identify these conditions, a symptom diary could be advised.
Some protective advices should be given to the patient to be performed during
the attack. Also most of the patients tend to close their eyes during the attack, and it
should be taught that keeping their eyes open and targeting them onto something
would help them to suppress nystagmus [127]. Instead of panicking over symptoms,
they should be advised to stay calm and sit or lie down in order to prevent them-
selves from further injuries.
When the attack subdued, refractory effects could continue to debilitate the
patient. The patient should be advised to avoid any sudden movements. In order to
minimize the effects on their personal lifestyles, some modifications should be
advised like performing daily activities, sitting instead of standing while cooking,
dressing up, etc.
In order to prevent patients’ social isolation, patients should be encouraged
about informing their social circle about their condition. Also series of exercises
should be programmed for each patient’s current status, and patients should be
encouraged to participate in social life. In our clinic, we advise our patients to go to
a mall for window shopping. It helps patients to overcome their fear to be in public,
helps them to use visual object to train their vestibulo-ocular system, and also
improves their walking and sense of proprioception. In addition to these advises, if
a specific problem was found on their posturography, it is consulted with related
departments.
Rehabilitation and its importance are well documented in Meniere’s disease
patients who received a destructive protocol [133–135]. However, studies about the
effects of vestibular rehabilitation on patients who suffer from post-vertigo dis-
equilibrium are limited. Clendaniel and Tucci reported the importance of vestibular
rehabilitation of patients after vertigo attack [136].
Gottshall et al.’s study demonstrated the beneficial effects of vestibular exercises
on post-vertigo symptoms with unilateral Meniere’s disease. Patients reported that
their balance function was significantly improved, only experiencing subtle dis-
comfort [137]. In bilateral disease, it is reported by Cohen et al. that vestibular
rehabilitation was not effective and advised to evaluate other adaptive strategies
with these patients [138].
Vestibular rehabilitation between attacks could help patients to cooperate with
disease and help them to keep their functionality levels up. Vestibular rehabilita-
tion’s effect on patients’ mental status is not reported in the current literature but
logically it could improve mental health. Recent guidelines recommend behavioral
therapies and vestibular rehabilitation programs.
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5.4 Hearing loss and tinnitus in Meniere’s disease
Meniere’s disease symptoms are episodic vertigo attacks, fluctuating hearing
loss, tinnitus, and ear fullness. Most disturbing symptom of this condition is vertigo
according to most of the studies that evaluated the quality of life scores of the
patients. So the preservation of hearing function and reducing the tinnitus intensity
are always evaluated as secondary outcomes in studies. During follow-up of the
patients, it is important to document hearing levels because remained hearing
function is the key factor in decision-making process of the treatment.
One of the diagnostic criteria of Meniere’s disease according to AAO-HNS’s
guideline is hearing loss.
It is recommended to stage the disease and underline as an important factor to
monitor the treatment results [11].
In ICON’s guideline, destructive treatment options are recommended if there is
no functional hearing left [59]. Hearing loss is usually located in lower frequencies,
and in early stages of the disease, it has a fluctuating pattern [139, 140]. In later
phases, it could decrease, and after 5–10 years, hearing thresholds usually settle to
50–60 dB as well as speech discrimination scores decrease to 50–60% [141]. Tinni-
tus is mostly a low-frequency type due to hearing loss, which could be localized to
affected ear and could be described globally [38]. Low-frequency tinnitus is diffi-
cult to be masked with environmental sounds [142].
Havia et al. reported the relationship between vertigo, hearing loss, and tinnitus.
Patients with more profound hearing loss had worse outcomes on their
posturography tests and caloric test responses found decreased on the affected ear
[35]. Recent studies demonstrated that hearing loss in these patients is associated
with sensory element degeneration [143].
The intensity of tinnitus reported to increase with duration symptoms. Intense
tinnitus is found to be related with hearing loss specifically at 500 Hz. However,
vertigo attack frequency or duration of the attacks was not related with tinnitus
intensity [35]. Gentamicin injections proven to be effective to reduce the tinnitus
but surgical interventions found to be ineffective on tinnitus control [144, 145]. In
order to compensate with tinnitus, behavioral therapy should be advised.
Betahistine and nasal oxytocin were studied in Meniere’s disease and they reported
to decrease tinnitus perception but data are limited [146, 147]. Cochlear implants
have reported that they decrease tinnitus significantly; although the data are
limited and still relatively new, it is reported to decrease tinnitus of patients after
6 months [148].
5.5 Treatment of bilateral Meniere’s disease
Bilateral Meniere’s disease prevalence is reported in 2–47% of the cases, and it
could occur after several years of the first onset of the disease [9]. Temporal bone
studies suggest that bilateral Meniere’s disease incidence is higher and bilateral
endolymphatic hydrops observed 25–30% of the inspected temporal bones [149–
151]. Bilateral Meniere’s disease should be treated conservatively; bilateralization
could occur at any time, and there is no test that could prevent this. This condition
is the main reason of the emphasis on being conservative while choosing the treat-
ment option.
Meniere’s disease rarely start bilaterally, it usually starts with unilaterally
[152–154]. Most of the cases, contralateral involvement occurs after 2–5 years after
the first initiation of symptoms [155]. Clinical presentation of these cases is differ-
ent from each other. Most important step in diagnosis is suspicion and knowledge of
the possible nature of the disease could affect the contralateral side at some point of
patients’ follow-up. Severity of the disease should be established independently for
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each ear, in pure-tone audiometry average of 500, 1000, 2000, and 3000 Hz >25 dB
[11]. Tinnitus is reported to be more intense in bilateral Meniere’s patients. Also
they reported that patients who had bilateral Meniere’s disease had significantly
longer history of disease and worse pure-tone average [35].
In EcoG, Iseli and Gibson reported that summation potential/action potential
ratio has a limited value to determine endolymphatic hydrops and should be com-
bined with summation potential amplitude ans summating potential bias ratio
[156]. Lin et al. proposed to combine VEMP tuning and VEMP thresholds to detect
the hydrops in the contralateral ear before the symptoms’ onset [157]. In imaging,
studies suggest that affected side has endolymphatic dilatation and due to this
perilymph volume seem decreased [158]. Combination of these diagnostic strategies
could help physicians to detect bilateral involvement and avoid from destructive
procedures in suspected patients.
In ICON’s guideline, they reported that the bilateral tendency of the disease
attributed as an important factor of most clinic treatment protocol shift from
intratympanic gentamicin to intratympanic steroid. Also as a surgical treatment
option, endolymphatic sac procedures are recommended for bilateral Meniere’s
disease [59]. In SFORL guideline, gentamicin injections are contraindicated in single
intact ear or bilateral Meniere’s disease. They recommend endolymphatic sac sur-
gery if medical treatments failed in bilateral Meniere’s disease. Destructive surgeries
such as vestibular neurectomy and labyrinthectomy are not recommended in bilat-
eral Meniere’s disease [54].
Treatment options of bilateral disease are restricted. Conservative treatment
options should be advised and symptomatic treatment should be prescribed during
attack. Peterson et al. conduct a survey study among American otorhinolaryngolo-
gists about their choice of treatment with patient who had only hearing ear and
most common option is Meniett device when other conservative treatment options
failed. After Meniett, intratympanic steroid injection comes second in their choice
of treatment. Endolymphatic sac procedures come in third; first decompression is
advised than shunt procedures. Selective vestibular nerve section comes later [107].
Intratympanic steroid injection could be advised to patients with bilateral
Meniere’s disease. Recent randomized controlled study conducted in 2005 reported
that intratympanic steroid injections are the effective way of treatment [159].
However, another study found no difference between intratympanic steroid injec-
tion and saline injection [160, 161]. The literature findings are controversial.
Intravenous streptomycin sulfate in debilitating bilateral Meniere’s disease
reported to reduce the symptoms [162–164]. If complete or near complete bilateral
hypo-function has occurred, streptomycin sulfate is found to be effective [163].
Immune-mediated bilateral Meniere’s disease is a subgroup of Meniere’s disease,
and methotrexate treatment is found to be effective on symptom control [165].
Another treatment option for immune-mediated group is systemic steroids, its
efficacy is reported in a few studies [153, 166–170]. Prospective study on treatment
of bilateral Meniere’s disease with systemic steroids reported significant improve-
ment on decrease in vertigo attacks but had no effect on hearing loss or tinnitus or
aural fullness [170].
Surgical option of these patients is endolymphatic sac surgery; it has lowest
complication rates on sensorineural hearing loss, <2% [171]. Kitahara et al.’s study
reported the results of patients who had endolymphatic sac drainage with and
without insertion of steroid induced silastic and nonsurgical group. The vertigo
control rates were similar in surgery groups with or without steroid, but hearing
levels of steroid group had better long-term results than nonsteroid surgery group
and nonsurgical group [172]. Their findings were also supported with review of
Wetmore. In order of retractable disease ablative surgeries combined with cochlear
implant insertion should be considered.
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